http://www.diva-portal.org
This is the published version of a paper published in The Lancet.
Citation for the original published paper (version of record):
Byass, P. (2016)
Child mortality is (estimated to be) falling.
The Lancet, 388(10063): 2965-2967
https://doi.org/10.1016/S0140-6736(16)32169-9
Access to the published version may require subscription.
N.B. When citing this work, cite the original published paper.
Permanent link to this version:
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-128408
Comment
www.thelancet.com Vol 388 December 17/24/31, 2016 2965
Undoubtedly child mortality is falling, and the world should be proud of this progress. Within the past 100 years, expectations around child mortality (and subsequentl y family size) have changed substantially, starting in countries that industrialised earlier and more recently pervading most of the world. Li Liu and colleagues,
1in The Lancet, describe detailed fi ndings on the latest state of global child mortality. Naturally the levels of detail—by location, time, age, and cause of death—at which these fi ndings can be presented in a single scientifi c article are limited, although a fi ner level of detail is available as online material. Liu and colleagues
1report that in 2015, among the 5·9 million under 5 deaths, 2·7 million are now estimated to occur in the narrow time window of the neonatal period (fi rst 28 days of life), mainly around delivery or due to subsequent infections. They report that the leading under-5 causes of death were preterm birth complications (1·055 million), pneumonia (0·921 million), and intrapartum related events (0·691 million). Sub-Saharan Africa and Asia account for more than 80% of all under-5 deaths, with post-neonatal deaths mainly attributable to childhood infections and injuries. Reductions in mortality from pneumonia, diarrhoea, neonatal intrapartum related events, malaria, and measles were responsible for 61% of the total reduction of 35 per 1000 livebirths in under-5 mortality rates in 2000–15.
These headline outcomes were also refl ected closely in the recently updated Global Burden of Disease Study estimates.
2Seeing diff erent approaches leading to very similar fi ndings in the two sets of estimates suggests high covalidity. All of these headline fi ndings invite further exploration of the underlying detailed resources. Estimated numbers of child deaths are important, but are not very useful unless they are continually probed, interpreted, and applied into health policy solutions.
The UN Millennium Development Goals (MDGs), specifi cally MDG 4, have rightly focused considerable attention on child mortality in recent years.
3Although Liu and colleagues
1acknowledge that the goal of a two-thirds reduction in under-5 child mortality from 1990 to 2015 did not happen globally, more nuanced consideration needs to be applied to understand changing patterns of child mortality. Global goals and targets tend to be set on a one-size-fi ts-all basis, as was the case with the MDGs. However, there are notable exceptions. In 1990, South Africa had the lowest under-5 mortality rate in the sub-Saharan region, then encountered a massive HIV pandemic, but subsequently achieved a substantial improvement in child mortality towards the end of the MDG period. Using in-country data to reveal the details, this was dubbed ‘‘a successful failure’’ in terms of
Child mortality is (estimated to be) falling
Thomas H Gillingwater
Euan MacDonald Centre for Motor Neurone Disease Research and Centre for Integrative Physiology, Edinburgh Medical School:
Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
T.Gillingwater@ed.ac.uk
I am Chair of the Scientifi c Advisory Board of the SMA Trust and serve on scientifi c and clinical advisory boards for SMA Europe and Association Française contre les Myopathies. I am named on a patent application submitted by the University of Edinburgh for the use of β-catenin inhibitors for the treatment of spinal muscular atrophy.
1 Lefebvre S, Bürglen L, Reboullet S, et al. Identifi cation and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–65.
2 Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label study. Lancet 2016;
published online Dec 6. http://dx.doi.org/10.1016/S0140-6736(16)31408-8.
3 Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy:
controversies and challenges. Lancet Neurol 2012; 11: 443–52.
4 Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.
Proc Natl Acad Sci U S A 1999; 96: 6307–11.
5 Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008; 82: 834–48.
6 Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Sci Transl Med 2011; 3: 72ra18.
7 Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy.
Neurology 2016; 86: 890–97.
8 Kariya S, Obis T, Garone C, et al. Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.
J Clin Invest 2014; 124: 785–800.
9 Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013; 19: 40–50.
10 Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123–26.
11 Hosseinibarkooie S, Peters M, Torres-Benito L, et al. The power of human protective modifi ers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet 2016;
99: 647–65.
12 Wishart TM, Mutsaers CA, Riessland M, et al. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy.
J Clin Invest 2014; 124: 1821–34.
Published Online November 10, 2016 http://dx.doi.org/10.1016/
S0140-6736(16)32169-9 See Articles page 3027
Comment
2966 www.thelancet.com Vol 388 December 17/24/31, 2016
MDG 4.
4Additionally, country-level estimates could well obscure major geographical or socioeconomic inequalities in mortality that might well exceed intercountry diff erences.
In view of the substantial eff orts that go into assessing global patterns of childhood mortality, it is important to consider additional creative ways of using and interpreting such fi ndings. As well as the obvious need to monitor levels and trends of mortality over time and hold governments to account, mortality rates might also provide crucial pointers to other health and disease issues at the population level. Early life exposures are critically important
5and can exert epigenetic changes that aff ect the whole life-course, as expressed in the Developmental Origins of Health and Disease (DOHaD) hypothesis.
6Ideally, individual life-course information linking community and health facility events is needed to understand such processes, but rarely exists in low- income and middle-income countries.
7Clearly, early childhood death data cannot substitute on an individual basis for life-course details. However, each early child death probably refl ects a similar set of exposures among a wider surviving peer-group, and making that connection could enable the application of indirect analytical methods, such as longitudinal estimates of population-attributable risks, to elucidate the health impacts of early stresses on later life.
In considering Liu and colleagues’ work,
1the world should not be proud of the persisting technical requirement to say that child mortality is estimated to be falling. Of the estimated 6 million under-5 child deaths in 2015, only a small proportion were adequately documented at the individual level, with particularly low proportions evident in low-income and middle-income countries, where most childhood deaths occur. Liu and colleagues,
1as well as other international groups,
2have made impressive methodological progress in applying increasingly sophisticated mathematical and computing techniques to the scant available data on child mortality, to arrive at reasonable estimates. Nevertheless, the proportion of child lives and deaths individually documented has not increased nearly as rapidly as (estimated) rates of child mortality have decreased.
Despite the global information revolution—resulting in a single modern 256 gb laptop having enough capacity to hold a 250-character record on each of the 670 million under-5 children in the world, with space
left over for full details of each of the 6 million annual under-5 deaths—such data are simply neither collected nor available.
7That 6 million under-5 children continue to die every year in our 21st century world is unacceptable, but even worse is that we seem collectively unable to count, and hence be accountable for, most of those individual deaths. A suggestion 5 years ago was that the MDGs lacked the hypothetical MDG 0, to increase coverage of individual vital registration beyond 95%.
8Instruments and expertise to expand civil registration and vital statistics (CRVS) still need much wider application.
9Automated verbal autopsy needs deploying as a routine part of CRVS, to track individual cause-of-death and decrease dependence on estimates.
10Disappointingly, the new Sustainable Development Goals (SDGs) do not explicitly mandate registering and counting major life events as the foundation for monitoring human health and development.
11Target 16.9, which calls for universal birth registration by 2030, almost implies by omission that registering other life events is unimportant, although Target 17.19 wishes for improved statistical capacity in general. But when will the world learn that slogans like “Everyone counts—so count everyone” need to translate urgently into large-scale, globally funded actions that are determined to value every individual as the basic unit of observation for understanding and improving global health?
12Peter Byass
Umeå Centre for Global Health Research, Epidemiology and Global Health, Department of Public Health and Clinical Medicine, Umeå University, Umeå 90187, Sweden; and Stellenbosch Institute for Advanced Study (STIAS), Wallenberg Research Centre at Stellenbosch University, Stellenbosch, South Africa peter.byass@umu.se
I declare no competing interests.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
1 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016; published online Nov 10.
http://dx.doi.org/10.1016/S0140-6736(16)31593-8.
2 GBD 2015 Child Mortality Collaborators. Global, regional, national and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1725–74.
3 United Nations. The Millennium Development Goals Report 2015.
New York: United Nations, 2015. http://www.un.org/
millenniumgoals/2015_MDG_Report/pdf/MDG 2015 rev (July 1).pdf (accessed Sept 23, 2016).
Hossein Fatemi/Panos
Comment
www.thelancet.com Vol 388 December 17/24/31, 2016 2967
4 Byass P, Kabudula CW, Mee P, et al. A successful failure: missing the MDG4 target for under-fi ve mortality in South Africa. PLoS Med 2015; 12: e1001926.
5 Black MM, Walker SP, Fernald LCH, et al. Early childhood development coming of age: science through the life course. Lancet 2016; published online Oct 4. http://dx.doi.org/10.1016/S0140-6736(16)31389-7.
6 International Society for Developmental Origins of Health and Disease.
The Cape Town Manifesto—November, 2015. Cape Town: International Society for Developmental Origins of Health and Disease, 2015. https://
dohadsoc.org/wp-content/uploads/2015/11/DOHaD-Society-Manifesto- Nov-17-2015.pdf (accessed Sept 26, 2016).
7 Byass P. The unequal world of health data. PLoS Med 2009, 6: e1000155.
8 Byass P, Graham W. Grappling with uncertainties along the MDG trail.
Lancet 2011; 1119–20.
9 AbouZahr C, de Savigny D, Mikklesen L, et al. Towards universal civil registration and vital statistics systems: the time is now. Lancet 2015;
386: 1407–18.
10 Byass P. Cause-specifi c mortality fi ndings from the Global Burden of Disease project and the INDEPTH Network. Lancet Glob Health 2016;
4: 785–86.
11 United Nations. Transforming our world: the 2020 Agenda for Sustainable Development. New York: United Nations, 2015.
https://sustainabledevelopment.un.org/content/documents/21252030 Agenda for Sustainable Development web.pdf (accessed Sept 26, 2016).
12 Lo S, Horton R. Everyone counts—so count everyone. Lancet 2015;
386: 1313–14.
The war in Syria has reached extraordinary levels of human suff ering. Millions are displaced in Syria, throughout the region, and into Europe, an inestimable number of people killed, and hundreds of thousands are trapped in besieged areas. A popular uprising has been overtaken by a regional stand-off among great powers.
The path that led us here calls into harsh light the utter failure of global governance and action to intervene to protect vast populations from the atrocities of war. The promises made and structures established in the wake of World War 2 have been broken, crumbling under political stalemates and lack of leadership at the UN. What is most disturbing to people in the region is the indiff erence and silence from the major nation states that defi ned the post-war consensus on law and norms relating to treatment of civilian populations in war.
In this shadow, The Lancet and the American University of Beirut have together established the Commission on Syria: Health in Confl ict. The aim of the Commission is to describe, analyse, interrogate, and decry the calamity before us. The lens is health and wellbeing, always a productive way to assess grave issues of high mortality and morbidity, disruptions of home, family, settlement, environment, and such extensive loss that the future itself is hard to discern. With this Commission, we have embarked on the diffi cult eff ort to identify these costs and enumerate them where possible. Hence, the fi rst task ahead is to account for the burden of war. We will also examine the challenges of the international response to the crisis and learn the lessons for future crises. The Commission will develop concrete recommendations to address the unmet current and future health needs,
including those related to rebuilding and to strengthening the global health response to political confl ict.
At the Commission’s fi rst meeting in Beirut, Lebanon, on Dec 1–2, 2016, the participants recognised the terrible global meanings and dismal outlook of the confl ict in Syria. But as members of the global health community, we must acknowledge our collective responsibility to respond through what we do best: science and advocacy. In so doing, we hope to advance global research, collaboration, and advocacy on matters of life and death in confl ict—
certainly at the core of our mission as health professionals in a globalised and increasingly violent world.
Many of the events and facts are widely known, a point that further underscores the enormity of the crime of inaction. The carnage in the cities and villages of Syria has left at least 250 000 people dead, but recent
The Lancet–American University of Beirut Commission on Syria:
a new role for global health in confl ict and a call for papers
Associate Press
